Authors
Loading...
Multicenter cohort studies demonstrate hydroxyurea maintains safety during pregnancy, linking to live birth rates in sickle cell disease patients.
Habibi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: